Israel
peptic ulcer treatment market is expected to grow at an impressive rate during
the forecast period, 2024-2028. The major factors
include increasing prevalence of peptic ulcer
diseases, rising R&D activities and strong pipeline of new drugs, and increasing
investment for healthcare infrastructure. Also, the awareness is rising for
minimally invasive procedures for the treatment of peptic ulcers, which, in
turn, is expected to promote the growth of the Israel peptic ulcer treatment
market during the forecast period. According to National Institute of
Health, National Center for Biotechnology Information, Children in Israel have
a high prevalence and early acquisition of Helicobacter pylori (H. pylori)
that causes an infection in the stomach or duodenum (first part of the small
intestine) to further develop the peptic ulcer.
Peptic ulcers are sores in the lining of the stomach, lower
esophagus, or small intestine caused by inflammation from the bacteria
Helicobacter pylori (H. pylori) and stomach acid erosion. Peptic ulcers are generally caused
owing to radiation therapy, inflammation, and frequent use of aspirins
parentally or orally. Untreated peptic ulcers can lead to the complications
such as severe pain in upper or mid-body parts, severe blood loss, internal
bleeding, and weight loss, which may need instant hospitalization. The Israel
peptic ulcer treatment market is a growing market as the prevalence of peptic
ulcer disease increases due to factors such as stress, unhealthy diets, and
increased use of nonsteroidal anti-inflammatory drugs (NSAIDs).
Additionally, the rise in awareness related to complications
associated with peptic ulcer disease is a major factor that fuels the growth of
the Israel peptic ulcer treatment market. Moreover, increase in geriatric
population and sedentary lifestyle boost the growth of the market. However,
recent patent expirations are anticipated to hinder the growth of the Israel peptic
ulcer treatment market.
Increasing
Prevalence of Peptic Ulcer Diseases
One
of the primary drivers of the Israel peptic ulcer treatment market is the
increasing prevalence of peptic ulcer disease. This condition is becoming more
common nowadays, with an estimated 10% of the overall population affected. This
is due to various factors such as stress, unhealthy diets, and increased use of
nonsteroidal anti-inflammatory drugs (NSAIDs), which can contribute to the growth
of the Israel peptic ulcer treatment market.
Israel
has one of the highest rates of peptic ulcer disease in the world, with an
estimated 10%-15% of the population affected. This high prevalence has created a significant demand for effective
treatments, which has led to the introduction of new drugs in the market. In
Israel, drugs such as proton pump inhibitors (PPIs), H2 receptor antagonists
(H2RAs), and antibiotics are commonly used to treat peptic ulcers, and
pharmaceutical companies are investing in research and development of new and
improved drugs for this condition. The increasing prevalence of peptic ulcer
disease in Israel has also encouraged the adoption of advanced diagnostic and
treatment technologies, such as endoscopy and laser treatment. These
technologies allow for early detection and treatment of peptic ulcers, which
can improve patient outcomes and reduce healthcare costs. The high prevalence
of peptic ulcer disease in Israel has also led to the development of advanced
research centers, which are focused on the study of peptic ulcers and the
development of new treatments. These centers are staffed by leading experts in
the field of gastroenterology, and they collaborate with pharmaceutical
companies to develop new drugs and treatment methods. Therefore, peptic ulcers promote
the development of new and innovative drugs and encourage the adoption of
advanced diagnostic and treatment technologies. These factors are expected to
continue driving the growth of Israel peptic ulcer treatment market in the
coming years.
Rising
Number of R&D Activities and Strong Pipeline of New Drugs
The
growing number of peptic ulcer patients is motivating the key players present
in the market to invest in the research/development activities. This can
positive impact the growth of the Israel peptic ulcer treatment market. For
instance, a company namely RedHill Biopharma Ltd. received the United States
Food & Drug Administration (USFDA) approval for RHB-105(Talicia) to treat
Helicobacter pylori in adults in the US in March 2020.
Strong
market players are using their long-term strategies to acquire a competitive
advantage such as new product launches, collaboration partnerships, and upgradation
of products. Moreover, rising government investment for the development of
advanced technologies will further provide beneficial opportunities for the market
during the forecast period.
Several
clinical trials are going on for most of the drugs to overcome the
complications related to currently available drugs. This is another factor
which is likely to fuel the growth of the Israel peptic ulcer treatment market
during the forecast period. For instance, according to the clinicaltrials.gov,
a company namely Takeda Pharmaceuticals has a drug Vonoprazan fumarate in phase
3 trials, which is a drug of category potassium competitive acid blockers (P-CABs)
for peptic ulcer treatment market. Additionally, GlaxoSmithKline plc is another major player in the Israel peptic ulcer
treatment market. The company is focused on developing new therapies for peptic
ulcer treatment that target the underlying causes of the disease.
GlaxoSmithKline has several drug candidates in its pipeline, including
GSK-2330672, a novel H2 blocker that has shown promising results in early
clinical trials.
AstraZeneca
is a leading pharmaceutical company that is investing heavily in R&D to
develop new treatments for peptic ulcers. The company has several drug
candidates in its pipeline, including AZD-3342, a selective gastrin receptor
antagonist that is being developed for the growth of the Israel peptic ulcer treatment
market. The company is also investigating the use of combination therapies to
improve the efficacy of Israel peptic ulcer treatment market.
Increasing
Investment for Healthcare Infrastructure
Another
significant factor influencing the growth rate of the Israel peptic ulcers
market is the rising healthcare expenditure which helps in improving its
infrastructure. Also, various government organizations aim to improve the
healthcare infrastructure by increasing funding and this will further influence
the market dynamics.
Furthermore,
rising initiatives by public and private organizations to spread awareness will
expand the Israel peptic ulcers market. Additionally, the sedentary lifestyle
of people such as high alcohol consumption and addiction to smoking will result
in the expansion of the Israel peptic ulcer market. The rising level of
disposable income and surging geriatric population are the major factors
anticipated to flourish the market’s growth rate during the forecast period.
The
public health campaigns
have also played a role in increasing awareness of the health risks associated
with peptic ulcers in Israel. These campaigns aim to educate the public about
the importance of healthy lifestyle choices, such as diet and exercise, in
preventing hypertension. They also encourage people to get their blood pressure
checked regularly and to seek medical treatment for the sores present in the
inner lining of the stomach. In addition to public health campaigns,
educational programs and outreach initiatives have been implemented to induce
awareness regarding peptic ulcer diseases and its treatment in Israel. These
factors and programs give rise to the growth of the Israel peptic ulcer
treatment market.
Download Free Sample Report
Market Segmentation
The
Israel peptic ulcer treatment market can be segmented by product
type, disease indication, end user, and region. By product
type, the market can be segmented into proton pump inhibitors, H2 antagonists,
antibiotics, and others. Based on disease indication, the market can be segmented into gastritis, gastric ulcer, duodenal ulcer, and
gastroesophageal reflux disease (GERD). In terms of end users, the market
can be segmented into hospital
pharmacies, retail pharmacies, and online pharmacies.
Market Players
Pfizer Pharmaceuticals Israel
Ltd, AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel
Ltd, GlaxoSmithKline (Israel) Ltd, Takeda Israel Ltd., Israel B. Abbott., and
Phibro Israel are
some of the leading companies operating in the Israel Peptic Ulcer Treatment Market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2022
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume Units and
CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume forecast company share, competitive
landscape, growth factors, and trends
|
|
Segments covered
|
·
Product Type
·
Disease Indication
·
End User
·
Region
·
Company
|
|
Regional scope
|
The Mediterranean coastal plain, The Central Hills, The Jordan
Rift Valley, and The Negev Desert
|
|
Key companies profiled
|
Pfizer Pharmaceuticals Israel Ltd,
AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel
Ltd, GlaxoSmithKline (Israel) Ltd, Takeda Israel Ltd., Israel B. Abbott., and
Phibro Israel
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet
your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, the Israel peptic
ulcer treatment market has been segmented into following categories, in
addition to the industry trends which have also been detailed below:
·
Israel Peptic Ulcer Treatment Market, By Product Type
o
Proton
Pump Inhibitors
o
H2
Antagonists
o
Antibiotics
o
Others
·
Israel
Peptic Ulcer Treatment Market, By Disease Indication
o
Gastitis,
Gastric Ulcer
o
Duodenal
Ulcer
o
Gastroesophageal
Reflux Disease (GERD)
·
Israel
Peptic Ulcer Treatment Market, By End User
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
·
Israel Peptic Ulcer
Treatment Market, By Region:
o
The
Mediterranean coastal plain
o
The
Central Hills
o
The
Jordan Rift Valley
o
The
Negev Desert
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in the Israel peptic ulcer treatment market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
Detailed analysis and
profiling of additional market players (up to five).
Israel peptic ulcer treatment market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]